Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics
ELDN Price/Volume Stats
Current price | $2.26 | 52-week high | $2.95 |
Prev. close | $2.44 | 52-week low | $1.07 |
Day low | $2.11 | Volume | 2,532,800 |
Day high | $2.29 | Avg. volume | 120,957 |
50-day MA | $1.87 | Dividend yield | N/A |
200-day MA | $1.57 | Market Cap | 56.08M |
ELDN Stock Price Chart Interactive Chart >
Eledon Pharmaceuticals, Inc. (ELDN) Company Bio
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Latest ELDN News From Around the Web
Below are the latest news stories about ELEDON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELDN as an investment opportunity.
Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that on December 1, 2023, the Company’s Compensation Committee granted our new Chief Medical Officer, Eliezer Katz, M.D., inducement stock options to purchase an aggregate of 921,000 common shares, at a per share exercise price of $1.14, the closing price of Eledon’s common stock on December 1, 2023. The stock options were granted as inducements material to the new employee en |
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceIRVINE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming NobleCon19 - Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4, 2023, at 12:00 p.m. EST. Dr. Gros will also participate in a panel discussion titled: The Organ Transplant Revolution, that will take place on Monday, December 4, 20 |
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsReported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today reported its third quarter operating and financial |
Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceIRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies London Healthcare Conference on Thursday, November 16, 2023, at 8:00 a.m. GMT (3:00 a.m. EST). To register in advance for the presentation webcast, sign up here. A webcast replay will be accessible following the live session on the Events page of the Investors |
ELDN Price Returns
1-mo | 30.64% |
3-mo | 33.73% |
6-mo | 94.83% |
1-year | -17.82% |
3-year | -74.46% |
5-year | N/A |
YTD | 25.56% |
2023 | -21.05% |
2022 | -48.30% |
2021 | -71.36% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...